Biodexa Pharmaceuticals Plc (BDRX) stock
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.24−0.16 (-6.67%)
Close on Nov 16, 2026Market cap $5.06MP/E –Yield –
Biodexa Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Biodexa Pharmaceuticals's total debt was £61.00K at Dec 31, 2025. For fiscal 2025 it was £61.00K, down 91.6% from the year before. Over ten years it grew -29.3% a year on average. The highest annual figure on record is £6.55M in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £61.00K | -91.6% |
| FY2024 | Dec 31, 2024 | £727.00K | +56.7% |
| FY2023 | Dec 31, 2023 | £464.00K | -25.6% |
| FY2022 | Dec 31, 2022 | £624.00K | -18.5% |
| FY2021 | Dec 31, 2021 | £766.00K | +194.6% |
| FY2020 | Dec 31, 2020 | £260.00K | -95.7% |
| FY2019 | Dec 31, 2019 | £6.08M | +385.8% |
| FY2018 | Dec 31, 2018 | £1.25M | -80.9% |
| FY2017 | Dec 31, 2017 | £6.55M | +203.3% |
| FY2016 | Dec 31, 2016 | £2.16M | +10.7% |
| FY2015 | Dec 31, 2015 | £1.95M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | £61.00K | -88.8% |
| Q4 FY2024 | Dec 31, 2024 | £727.00K | +16.5% |
| Q2 FY2024 | Jun 30, 2024 | £208.00K | -72.8% |
| Q4 FY2023 | Dec 31, 2023 | £464.00K | +78.5% |
| Q2 FY2023 | Jun 30, 2023 | £544.00K | -91.1% |
| Q4 FY2022 | Dec 31, 2022 | £624.00K | -50.2% |
| Q4 FY2021 | Dec 31, 2021 | £766.00K | -88.3% |
| Q4 FY2020 | Dec 31, 2020 | £260.00K | -88.0% |
| Q4 FY2019 | Dec 31, 2019 | £6.08M | +211.9% |
| Q4 FY2018 | Dec 31, 2018 | £1.25M | – |
| Q4 FY2017 | Dec 31, 2017 | £6.55M | – |
| Q4 FY2016 | Dec 31, 2016 | £2.16M | – |
| Q4 FY2015 | Dec 31, 2015 | £1.95M | – |
See a number that looks wrong?